Table 3.
Genotype frequencies in patients with Hurthle cell neoplasms
| Gene | Polymorphism | Genotype | All patients (%) | PHWE | HCTA+HCTN (%) | HCTC (%) |
|---|---|---|---|---|---|---|
| SOD2 | rs4880; c.47C>T; p.Val16Ala | CC | 26 (21.7) | 0.903 | 12 (17.9) | 14 (26.4) |
| CT | 59 (49.2) | 34 (50.7) | 25 (47.2) | |||
| TT | 35 (29.2) | 21 (31.3) | 14 (26.4) | |||
| CAT | rs1001179; c.-262C>T; c.-262G>A | CC | 70 (58.3) | 0.907 | 35 (52.2) | 35 (66.0) |
| CT | 43 (35.8) | 30 (44.8) | 13 (24.5) | |||
| TT | 7 (5.8) | 2 (3) | 5 (9.4) | |||
| GPX1 | rs1050450; c.599C>T; p.Pro200Leu | CC | 63 (52.1) | 0.424 | 35 (51.5) | 28 (52.8) |
| CT | 51 (42.1) | 32 (47.1) | 19 (35.8) | |||
| TT | 7 (5.8) | 1 (1.5) | 6 (11.3) | |||
| GSTP1 | rs1695; c.341C>T; p.Ile105Val | CC | 54 (44.6) | 0.653 | 28 (41.2) | 26 (49.1) |
| CT | 52 (43.0) | 32 (47.1) | 20 (37.7) | |||
| TT | 15 (12.4) | 8 (11.8) | 7 (13.2) | |||
| GSTP1 | rs1138272; c.313A>G; p.Ala114Val | AA | 103 (85.1) | 0.159 | 58 (85.3) | 45 (84.9) |
| AG | 16 (13.2) | 8 (11.8) | 8 (15.1) | |||
| GG | 2 (1.7) | 2 (2.9) | 0 (0) | |||
| GSTM1 | Gene deletion | Wild type | 55 (50.9) | /a | 33 (50.8) | 22 (51.2) |
| Gene deletion | 53 (49.1) | 32 (49.2) | 21 (48.8) | |||
| GSTT1 | Gene deletion | Wild type | 93 (86.1) | /a | 54 (83.1) | 39 (90.7) |
| Gene deletion | 15 (13.9) | 11 (16.9) | 4 (9.3) |
a
HWE could not be evaluated for GSTM1 and GSTT1 as we were not able to distinguish between carriers of one or two copies of each gene.
HCTA = Hurthle cell thyroid adenoma; HCTC = Hurthle cell thyroid carcinoma; HCTN = Hurthle cell thyroid nodule; HWE = Hardy-Weinberg equilibrium